A coalition of 20 state attorneys general, led by Tennessee Attorney General Jonathan Skrmetti, has sent a letter to U.S. Secretary of State Marco Rubio raising national security concerns about Chinese suppliers of GLP-1 weight-loss drugs. The letter warns that Chinese-sourced active pharmaceutical ingredients for drugs including semaglutide, tirzepatide, and retatrutide may be connected to fentanyl precursor manufacturers.
The warning marks what the coalition describes as one of the first coordinated state-level efforts to frame GLP-1 supply chains as a national security issue, escalating regulatory pressure beyond conventional drug-safety concerns.
What happened
On September 25, 2026, the 20-state coalition sent a letter to Secretary Rubio citing concerns that Chinese GLP-1 suppliers could have ties to fentanyl precursor manufacturing. The letter specifically referenced the FDA’s Green List, created in September 2025, which the coalition said has allowed certain Chinese suppliers to ship GLP-1 drugs into the United States without advanced scrutiny.
The letter also highlighted findings from FDA inspectors that Harbin Jixianglong Biotech, a Chinese supplier, had acquired GLP-1 drugs from an unapproved facility and relabeled them before distribution.
Why it matters
The letter represents a significant escalation in how GLP-1 supply chains are being scrutinized. By linking Chinese API suppliers to fentanyl precursor manufacturing, the coalition is pushing the issue into national security territory rather than limiting it to standard drug-quality enforcement.
The warning could have downstream effects across several sectors:
- Telehealth companies that source Chinese GLP-1 APIs may face new restrictions or sourcing requirements.
- Compounding pharmacies relying on Chinese-sourced ingredients could see increased regulatory scrutiny.
- Importers of Chinese peptide ingredients may need to conduct enhanced due diligence.
- Consumers using compounded or imported GLP-1 products could experience supply disruptions.
What to watch next
Whether the federal government responds to the coalition’s letter with new import restrictions or changes to the FDA Green List will be a key development. State-level enforcement actions against pharmacies, telehealth platforms, or importers using Chinese-sourced GLP-1 ingredients are also possible. Additionally, the broader peptide and compounding industry should monitor whether other states join the coalition or pursue independent actions.
Sources
Industry information only. Not medical or legal advice.
